Literature DB >> 9635529

Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.

S Chang1, S L Parker, T Pham, A U Buzdar, S D Hursting.   

Abstract

BACKGROUND: Little is known about the cause of inflammatory breast carcinoma (IBC), the most aggressive form of breast cancer. To the authors' knowledge, no studies have investigated whether IBC risk factors are different from those for breast carcinoma overall, and there has been only one report of IBC incidence and survival patterns.
METHODS: The authors used data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute for the period 1975-1992 to calculate age-adjusted incidence and survival rates for 913 white and 121 African American women with IBC involving dermal invasion of lymphatic ducts and 166,375 white and 13,674 African American women with other types of breast carcinoma (non-IBC).
RESULTS: Between 1975-1977 and 1990-1992, IBC incidence doubled, increasing among whites from 0.3 to 0.7 cases per 100,000 person-years and among African Americans from 0.6 to 1.1 cases. However, rates for African Americans varied due to the small numbers of IBC cases. The twofold increase in IBC incidence was higher than that observed for non-IBC during the same period (27% for African Americans and 25% for whites). IBC patients were significantly younger at diagnosis than non-IBC patients; and among both IBC and non-IBC patients, African Americans were younger than whites. Overall survival was significantly worse for IBC patients than for non-IBC patients and for African Americans than for whites. Among whites, 3-year survival improved more for IBC patients than for non-IBC patients between 1975-1979 and 1988-1992, increasing from 32% to 42% for IBC patients (P=0.0001) and from 80% to 85% for non-IBC patients (P=0.0001).
CONCLUSIONS: The disparities observed in incidence trends and age at diagnosis, particularly according to race, highlight the need for further investigation of the differences between IBC and non-IBC incidence.

Entities:  

Mesh:

Year:  1998        PMID: 9635529

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  61 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

3.  Lymph node status in inflammatory breast cancer.

Authors:  Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang
Journal:  Breast Cancer Res Treat       Date:  2015-04-07       Impact factor: 4.872

4.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

5.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

6.  The current understanding of the molecular determinants of inflammatory breast cancer metastasis.

Authors:  Galina S Radunsky; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2006-04-27       Impact factor: 5.150

7.  Targeted treatment of advanced and metastaticbreast cancer with lapatinib.

Authors:  Brendan Corkery; Norma O'Donovan; John Crown
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

8.  Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Authors:  Mona M Mohamed; Eslam A El-Ghonaimy; Mohamed A Nouh; Robert J Schneider; Bonnie F Sloane; Mohamed El-Shinawi
Journal:  Int J Biochem Cell Biol       Date:  2013-11-26       Impact factor: 5.085

9.  Incidence of inflammatory breast cancer in women, 1992-2009, United States.

Authors:  Bryan Goldner; Carolyn E Behrendt; Hans F Schoellhammer; Byrne Lee; Steven L Chen
Journal:  Ann Surg Oncol       Date:  2013-12-24       Impact factor: 5.344

Review 10.  Lapatinib: new opportunities for management of breast cancer.

Authors:  Julia Liao; Michelle Gallas; Mark Pegram; Joyce Slingerland
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.